See all the latest news, blogs and updates from the medical sector.
Inspirational author from Ireland
Geraldine, a determined MPS mother and writer, has published a book sharing her experience and insight into raising a child with a severe...
MPS Society welcomes new UK Rare Diseases Framework
MPS Society welcomes new UK Rare Diseases Framework, a national vision to improve the lives of those living with rare diseases.
Lockdown positivity
We asked you what you're doing to keep positive and stay healthy during lockdown this time round. The COVID-19 pandemic has affected...
Treatment for Metachromatic Leukodystrophy (MLD) approved by the European Commission
MLD is a very rare, fatal genetic disorder caused by mutations in the ARSA gene which lead to neurological damage
Frequently asked questions about the vaccination programme for COVID-19
The BIMDG has prepared these responses to frequently asked questions about the vaccine progamme for COVID-19.
Daniella Vandepeer discusses her clinical trial experience
Daniella Vandepeer shares her experiences of family life on a clinical trial including her motivation for joining a trial, the difficulties the family faces and what she feels is important for others considering joining a clinical trial.
Louise's story - The Big Give Christmas Challenge 2020
Meeting families in person has supported my learning about these conditions and my understanding about the challenges families face.
Kelly Mills' charity appeal for MPS Society on Radio 4
Thank you so much to everyone who donated to the Radio 4 appeal after hearing Kelly talk about her daughter, Penny, and her experience of...
So what does clinical trial support services actually mean? Lianne from RDRP reveals all
From clinical trials support and specialist medical communications to research and real-world evidence, Rare Disease Research Partners...
AVROBIO announce collaborative research agreement with Manchester university for MPS II gene therapy
AVROBIO announce collaborative research agreement with Manchester university for MPS II gene therapy.